The Advanced Therapy Medicinal Products ( Shanghai ) Forum -- Global Gene & Cellular Immunotherapy Innovators Shanghai Forum 2024 will bring in fresh perspectives and establish an efficient platform for Academia & Industry to discuss about the Current and Future Perspectives of Advanced Therapy Medicinal Products ( ATMPs ), Promoting China Innovation and Strengthening Collaboration in the Advanced Therapies and Regenerative Medicine Space.

Brainstorm with over 100+ high caliber speakers and estimation to bring over 500+ Industry Stakeholders, Entrepreneurs, Cell and Gene Therapy Pioneers, Influencers and Pharma R&D professionals. With this in mind, The Themes of "Advanced Therapy Medicinal Products ( Shanghai ) Forum -- Global Gene & Cellular Immunotherapy Innovators Shanghai Forum 2024" will cover:

Gene & Cellular Immunotherapy Revolution:
* Current Status and Future Directions of Advanced Therapy Medicinal Products ( ATMPs ) Development
-- Cell Based Therapies: Key Considerations for Clinicians, Health Care Systems, International Societies and Regulatory Authorities
-- A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care
-- The CAR-T Cell Revolution: CAR T-Cell Therapy targeting Leukemia, Lymphoma, Multiple Myeloma and Future Hopes for Solid Tumors
-- Regulations and Platforms for Ensuring the Quality, Safety and Efficacy of CAR-T Cell Therapy Products in China
-- Genetically Enhanced T Cell Immunotherapies: From Academic Innovation to Industry Translation
-- Integration of Cell Therapy with Single Cell Multi-omics
-- Next Generation Gene-modified CAR-T Cellular Therapy: Universal CAR-T ( UCAR-T ) Cell Therapy Development; ‘ Off-the-Shelf ’ Allogeneic CAR T-Cell; Non-Gene-Edited Allogeneic CAR T-Cell
-- Developing Allogeneic NK Cancer Immunotherapy with iPSC Technology
-- Development iPSC-Derived Cell Therapies for Neurodegenerative Diseases
-- iPSC-based Cell Therapy and Gene Therapy Solutions for Major Neurodegenerative Diseases and CNS Disorders
-- Development Dual-Targeted CAR-T Therapy against Hematological Malignancies
-- Combination Therapy with CAR T Cells and Oncolytic Viruses: a New Era in Cancer Immunotherapy
-- Developing Unique CAR Macrophage Therapies to Treat Solid Tumors
-- CAR-T Therapy and Tumor Microenvironment
-- Synthetic Biology-inspired Cell-based Therapies and Gene Therapies
-- Discovery Space in T Cell Analytics in Potency and Functionality for CART Cell Therapy
-- mRNA Therapeutics Development, CMC, Analytical and Manufacturing
-- Human Gene Therapy: Current Hurdles and Future Developments
-- Developing China AAV Gene Therapy Products Lead the New Trend in the Area of Gene Therapy

* Advanced Therapies CMC, Quality and Analytical Characterization
-- Regulations and Platforms for Ensuring the Quality, Safety and Efficacy of Cell & Gene Therapy Products
-- Analytical Characterization & Comparability, Process Validation, Method Validation, CMC and Quality Control
-- Vector Analytics for Gene Therapy - Advances in Viral Vector Characterization -- Advanced Product Characterization to Ensure Comparability, Product Quality and Process Consistency
-- mRNA Therapeutics – Analytical and Bioanalytical Characterization
-- Optimizing Analytical Methods to Guarantee Safe, High Quality, Consistent & Efficacious Gene Therapy Products
-- CMC Technical and Regulatory Compliance to Empower Cell and Gene Therapy Products Development Roadmap
-- Emerging Science and Technologies to Enhance Cell and Gene Therapies Development
-- The Potency Assay Development, Optimization and Validation for Cell Therapy
-- Optimized Cell and Gene Therapies Process Development, Manufacturing, Cost, and Quality Efficiency towards Successful Commercialization
-- Validation of Flow Cytometry Methods in Cellular Therapies
-- Lifecycle Management for CAR-T Cell and Gene Therapy Products
-- Addressing the Complexity of Process Validation for Cell and Gene Therapy Product Quality Assurance
-- Advanced Therapies: Innovations in CMC -- ATMP present unique CMC challenges that may complicate development. Effective CMC strategies are crucial to the successful development and lifecycle management of these products

* Cell and Gene Therapy Bioprocessing, Commercialization Manufacturing and Supply Chain Strategies
-- Cell and Gene Therapy Bioprocessing, Commercialization Manufacturing and Supply Chain Strategies
-- The State of the ART of Manufacturing CAR T Cells and The Latest Advancements
-- Emerging Science and Technologies to Enhance Advanced CAR-T Cell Therapies Development and Manufacturing Commercialization
-- Global Manufacturing, Bioprocessing, Supply Chain, and Automation Strategies for Engineered T-Cell Therapies
-- Viral Vectors GMP Manufacturing and Plasmid DNA Manufacturing for Cell Therapy – in House Manufacturing versus Outsourcing
-- Quality by Design for Advanced Therapies: Cell Therapy Manufacturing Commercialization - Strategy and Challenges
-- Optimized Cell and Gene Therapies Process Development, Manufacturing, Cost, and Quality Efficiency towards Successful Commercialization
-- The Significance, Prospect, Risk Control of Fully Automated CAR T Cell Manufacturing
-- Scalable Manufacturing Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
-- Industrializing Cell & Gene Therapies: Managing Complexity Across the Ecosystem
-- Establishing a Robust, Scalable, Automated, Functionally - Closed Manufacturing Process to Support a Pipeline of Emerging CAR-T Cell Immunotherapy
-- The Demand of Novel Equipment for New Concept Cell Therapy Product
-- Managing the Complexity of the Supply Chain for Cell and Gene Therapies
-- Supply Chain Management & Logistics for Advanced Therapies: Implement Robust, Patient-centric Supply Chains for Clinical to Commercial Readiness

* The State of the Art of Cell & Gene Therapy Industry in China; Future Directions of Cell & Gene Therapy in China
-- Development of Safe and Potent CAR-T Cell Therapy in China targeting Hematological Malignancies and Solid Tumor
-- Innovative Immuno-Cellular Therapy for R/R ALL
-- Driving CAR-T/TCR-T-cell-based Cancer Immunotherapy to Solid Tumors
-- Development Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy for the Treatment of Advanced Solid Tumors
-- Precision Immunotherapy: Development BCMA-Targeted CAR T-Cell Therapy for R/R Multiple Myeloma
-- Synthetic Biology-based Cell Engineering Technology beyond CAR T cells
-- Mechanisms & Clinical Study of CAR-NK Cell Drugs to Treat Solid Tumors
-- Engineering TCR-based Cell Immunotherapy against Cancer and Viral Infection
-- TCR Design, Engineering, Translation and Development Strategies for Solid Tumor Success
-- Opportunities and Challenges for TCR-T cell-based Immunotherapy against Solid Cancers
-- Drivers & Challenges for TIL Immunotherapy in Solid Tumor Treatment
-- TIL Therapeutics in Solid Tumor: Advantages, Challenges and Development Trends
-- Development ‘ Off-the-shelf ’ Allogeneic CAR T Cells: Development, Challenges and Prospects
-- Maximizing the Therapeutic Potential of CAR-T Cell Therapy Using CRISPR/Cas9 Gene-Editing Technologies
-- Leading the Innovation of Off-the-Shelf Universal CAR-T Cell Therapy Products Development by Gene Editing
-- Development of a Non-Gene-Edited Allogeneic CAR T-Cell Product in Hematological Malignancy
-- Development of Universal Cell Products from Stem Cell Based Platform from Bench to Bedside

* Human Gene Therapy / Future of AAV - rAAV Gene Therapy / Gene Therapies in Ophthalmic Diseases / Innovation of Gene Therapy Research for Rare Diseases & Neurodegenerative Diseases
-- Human Gene Therapy: Current Hurdles and Future Developments
-- Developing China AAV Gene Therapy Products Lead the New Trend in the Area of Gene Therapy
-- Regulation of Regenerative Medicine and Gene Therapy Research in China
-- Developing AAV-Based Gene Therapy Products in China for Leber’s Hereditary Optic Neuropathy
-- Developing Gene Therapy for Hemophilia A
-- AAV Vector Development and Viral Vector Manufacturing
-- Gene Therapy Development for Neurological Diseases
-- Development Gene Therapy based on Synthetic Biology
-- microRNA Gene Therapy
-- Progress of Gene Therapy in Duchenne Muscular Dystrophy
-- Bacterial Vector Gene Therapy for Intestine-associated Diseases
-- Translating Revolutionary Gene Editing Technologies into Potential Transformative Therapies
-- Base Editing Gene Therapy
-- The Investment and Venture Opportunities in Gene Therapy

* Gene Therapy Process Development, CMC and Manufacturing
-- General Technical Requirements for Production and Quality Control of Human Gene Therapy
-- AAV-based Gene Therapy Process Development, CMC, Analytical Development and Manufacturing Considerations
-- Gene Therapy Process Development, Analytics and Manufacturing Considerations
-- Vector Analytics for Gene Therapy - Advances in Viral Vector Characterization
-- Advanced Product Characterization to Ensure Comparability, Product Quality and Process Consistency
-- Optimizing Analytical Methods to Guarantee Safe, High Quality, Consistent & Efficacious Gene Therapy Products
-- Gene Therapy AAV Vector Process Development Strategies for Clinical Material Manufacturing
-- Plasmid Production: from Seeds to Release Testing / Manufacturing of Plasmids for Gene Therapies
-- Virus and Pathogen Clearance and Safety in Advanced Therapy Medicinal Products
-- Strategies to Deliver Scalable and Reliable Lentiviral Vector Bio-manufacturing and Gene Therapy Vector Production
-- Parallel GMP Manufacturing to Develop Gene Therapies in Both the US and China

* mRNA-based Therapies Development, Delivery Technologies Innovation, Analytical Characterization and Manufacturing
-- Strengthening Collaboration for Development and Commercialization mRNA-based Therapies in China
-- mRNA Therapeutics – Analytical and Bioanalytical Characterization
-- Challenge of mRNA CMC Development and Manufacturing
-- mRNA Manufacturing
-- Advancing siRNA Therapeutics for Enhancing Antitumor Activity of Immune Checkpoint Inhibitor
etc.,